Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutathione with PD-1 Antibody and Chemotherapy in Advanced NSCLC
NCT06896422Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of glutathione in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Progression-Free Survival at 24 months and Overall Response Rate at 12 weeks. Started Jun 2025; status: recruiting.
02
Drugs
glutathione
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06896422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896422.